AlphAIAlphAI — Financial news for AI agents
tradingview.com$CTSO

CTSO Q3'26 Earnings: revenue estimate is 9.90M USD

Cytosorbents Corporation (CTSO) will release Q3'26 earnings on October 29. Analysts expect revenue of $9.90M and EPS of -$0.90. The announcement is scheduled for 8:00 AM ET.

Original reporting
tradingview.com
Published Oct 22, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CTSO Q3'26 Earnings: revenue estimate is 9.90M USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$CTSONeutralLow
01

Why it matters

The earnings preview provides limited actionable insight; investors may watch the actual release for any deviation.

02

Market read

Low relevance; the guidance is modest and the company is small, offering little immediate trading opportunity.

03

What to watch

Potential upcoming regulatory approvals or partnership announcements not mentioned could offset guidance weakness.

Relevance 4/10Novelty 2/10Timing: pre‑earnings release (before Oct 29)

Background

Cytosorbents is a micro‑cap biotech company focused on blood purification technologies.

Company-level read

Ticker impact

$CTSONeutralMedium confidence
Context

CTSO (Cytosorbents) will announce Q3'26 results on Oct 29 with a revenue estimate of $9.90M and EPS of -$0.90.

Expected impact

potential modest downside if actual results miss the already low guidance

Evidence & confidence

Guidance is below breakeven; investors may react negatively but the small size limits impact.

Market effects

Sector

Limited impact on the broader biotech/medical device sector; Cytosorbents is a micro‑cap with niche market.

Regional

Primarily U.S. OTC market; unlikely to affect regional indices.

Global

Minimal global relevance due to company size and niche focus.

Counterpoint

What could challenge this read

If the market overreacts to the low guidance, a short‑term bounce could occur on any positive surprise.

Key entities

  • company
    Cytosorbents Corporation

    Developer of blood purification devices, ticker CTSO.

Read at source← All news

Related articles

$CTSOMed

CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update Delivering on…

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update Delivering on the First of Four Distinct Value Drivers PRINCETON, N.J., November 12, 2026 — CytoSorbents Corporation (NASDAQ

SEC EDGAR 8-K
$CTSOMed

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.

fool.com
$CTSOMed

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of…

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatme

SEC EDGAR 8-K
$CTSOMedAI 9/10

Cytosorbents (CTSO) Q1 2026 Earnings Transcript

Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.

fool.com
$AGROHighAI 8/10

Adecoagro (AGRO) Q3 2026 Earnings Call Transcript

Adecoagro reported Q3 2026 earnings, with gross sales of $591M and year-to-date sales of $1.5B. Fertilizers drove growth, offsetting lower Sugar, Ethanol, and Energy revenues. Adjusted EBITDA reached a 9-month high. The company acquired the Caarapó mill, expecting it to boost crushing volumes. Fertilizers and Food/Agriculture segments performed strongly, while Sugar/Ethanol faced cost pressures and lower sales.

finance.yahoo.com